UF Innovate | Sid Martin Biotech

Glint Pharmaceuticals Receives FDA IND Acceptance for Clinical Study for Phase 1/2 Clinical Trial of Antibiotic Drug-Releasing Contact Lens, ACL5

UF startup Glint Pharmaceuticals (Glint), a clinical-stage biotechnology company focused on developing a next-generation contact lens drug delivery technology, announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its antibiotic drug delivery contact lens, ACL5. Glint anticipates beginning the investigation in Q2 2023.

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement To Evaluate a Novel Device To Improve Patient Experience and Access to Neurological Aso Therapies

Biogen Inc. and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRxTM  System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreement, Biogen aims to leverage the ThecaFlex DRxTM System with a goal of improving the patient treatment experience and accessibility for a broader population of people suffering from neurological disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).

From Fighting Shoplifting to Pioneering Gene Therapies, the Startups in This Accelerator Are on the Front Lines of “Super Creativity”

The startups within UF Innovate, as well as the accelerator itself, are vivid examples of what creativity and innovation expert James Taylor, based in Scotland, describes as SuperCreativity—a phenomenon that many business leaders are trying to foster in today’s fast-changing business environment. It is a concept that goes beyond creativity or innovation alone.

UF AI Center To Push Boundaries of Ag Research

AI will create a fourth agricultural revolution, achieving huge gains in farm productivity the way the introduction of tractors, synthetic fertilizers and genetics did in previous eras. The speed and success of that revolution depends on how well land-grant university innovators. The groundwork for the revolution has been laid by more than a century of UF/IFAS establishing credibility through its citrus science. Working with a UF/IFAS faculty member comes with assurance that growers’ data will be protected.

Concept Companies and Lacerta Therapeutics Form a Strategic Partnership Around Facilities Expansion and Financing

Concept Companies, a national commercial real estate developer with a specialty across multiple asset classes including science and technology, and Lacerta Therapeutics, Inc., a leader in the AAV gene therapy space, today announced a strategic collaboration providing Lacerta with access to financing to support expansion of operations and new facilities. The financing is being provided via Agility Venture Capital, the funding arm of Concept Companies. 

Lacerta and Prevail, a Wholly Owned Subsidiary of Lilly, Sign Agreement To Develop Novel AAV Capsids for CNS Disorders

Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.

The Emerging Field of Regenerative Medicine: Personalized, Precision Medicine

Regenerative medicine, in conjunction with personalized medicine, is responsible for the next major paradigm shift in modern medicine. However, neither regenerative nor personalized precision medicine are subjects traditionally found in the curriculum of U.S. medical schools. As such, this emergence has been met with skepticism, doubt and confusion.